BeyondSpring Stock Drops Below 50-Day Average

Analysts Recommend Selling as Biotech Stock Declines

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

BeyondSpring Inc. (NASDAQ:BYSI) shares have fallen below their 50-day moving average, prompting concerns among analysts that the biotech stock may be a sell. The company's stock price has dropped to $1.49 per share, with trading volume of 12,878 shares.

Why it matters

BeyondSpring is a clinical-stage biopharmaceutical company focused on developing cancer treatments. The drop in its stock price below the 50-day moving average is a technical indicator that the stock may be in a downward trend, which could signal potential issues with the company's performance or outlook.

The details

According to data from MarketBeat, one research analyst has rated BeyondSpring stock as a "sell (d+)" based on the company's recent financial and operational performance. The stock has a 50-day moving average of $1.53 and a 200-day moving average of $1.76, indicating a broader decline in the share price over time.

  • BeyondSpring's stock price crossed below its 50-day moving average during trading on Thursday, March 6, 2026.
  • The stock has a 50-day moving average of $1.53 and traded as low as $1.46 on the day.

The players

BeyondSpring Inc.

A clinical-stage biopharmaceutical company focused on developing cancer treatments, headquartered in Suzhou, China with operations in New York.

Weiss Ratings

A research firm that has rated BeyondSpring stock as a "sell (d+)".

State Street Corp

An institutional investor that recently purchased a new position in BeyondSpring stock, owning about 0.57% of the company.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The decline in BeyondSpring's stock price below its 50-day moving average is a concerning technical indicator that may prompt some investors to consider selling the stock, especially given the negative rating from one research analyst. However, the company's long-term prospects will depend on the success of its clinical pipeline and its ability to navigate the competitive biopharmaceutical landscape.